Literature DB >> 16616331

The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity.

Yizhou Liu1, Matthew D Cheney, Justin J Gaudet, Maksymilian Chruszcz, Stephen M Lukasik, Daisuke Sugiyama, Jeff Lary, James Cole, Zbyszek Dauter, Wladek Minor, Nancy A Speck, John H Bushweller.   

Abstract

AML1/ETO is the chimeric protein resulting from the t(8;21) in acute myeloid leukemia. The Nervy homology 2 (NHR2) domain in ETO mediates oligomerization and AML1/ETO's interactions with ETO, MTGR1, and MTG16, and with the corepressor molecules mSin3A and HDAC1 and HDAC3. We solved the NHR2 domain structure and found it to be an alpha-helical tetramer. We show that oligomerization contributes to AML1/ETO's inhibition of granulocyte differentiation, is essential for its ability to enhance the clonogenic potential of primary mouse bone marrow cells, and affects AML1/ETO's activity on several endogenous genes. Oligomerization is also required for AML1/ETO's interactions with ETO, MTGR1, and MTG16, but not with other corepressor molecules.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616331     DOI: 10.1016/j.ccr.2006.03.012

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  66 in total

Review 1.  RUNX1-dependent mechanisms in biological control and dysregulation in cancer.

Authors:  Deli Hong; Andrew J Fritz; Jonathan A Gordon; Coralee E Tye; Joseph R Boyd; Kirsten M Tracy; Seth E Frietze; Frances E Carr; Jeffrey A Nickerson; Andre J Van Wijnen; Anthony N Imbalzano; Sayyed K Zaidi; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2018-12-04       Impact factor: 6.384

2.  AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation.

Authors:  X N Gao; F Yan; J Lin; L Gao; X L Lu; S C Wei; N Shen; J X Pang; Q Y Ning; Y Komeno; A L Deng; Y H Xu; J L Shi; Y H Li; D E Zhang; C Nervi; S J Liu; L Yu
Journal:  Leukemia       Date:  2015-03-02       Impact factor: 11.528

3.  Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization.

Authors:  Jun Zhou; Laurent Pérès; Nicole Honoré; Rihab Nasr; Jun Zhu; Hugues de Thé
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

4.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

5.  Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.

Authors:  Sangho Park; Wei Chen; Tomasz Cierpicki; Marco Tonelli; Xiongwei Cai; Nancy A Speck; John H Bushweller
Journal:  Blood       Date:  2009-02-09       Impact factor: 22.113

6.  Multivalent binding of the ETO corepressor to E proteins facilitates dual repression controls targeting chromatin and the basal transcription machinery.

Authors:  Chun Guo; Qiande Hu; Chunxia Yan; Jinsong Zhang
Journal:  Mol Cell Biol       Date:  2009-03-16       Impact factor: 4.272

7.  Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity.

Authors:  Yizhou Liu; Wei Chen; Justin Gaudet; Matthew D Cheney; Liya Roudaia; Tomasz Cierpicki; Rachel C Klet; Kari Hartman; Thomas M Laue; Nancy A Speck; John H Bushweller
Journal:  Cancer Cell       Date:  2007-06       Impact factor: 31.743

8.  CBFbeta is critical for AML1-ETO and TEL-AML1 activity.

Authors:  Liya Roudaia; Matthew D Cheney; Ekaterina Manuylova; Wei Chen; Michelle Morrow; Sangho Park; Chung-Tsai Lee; Prabhjot Kaur; Owen Williams; John H Bushweller; Nancy A Speck
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

9.  Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.

Authors:  Eun-Young Ahn; Ming Yan; Oxana A Malakhova; Miao-Chia Lo; Anita Boyapati; Hans Beier Ommen; Robert Hines; Peter Hokland; Dong-Er Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-24       Impact factor: 11.205

10.  Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.

Authors:  Russell C DeKelver; Ming Yan; Eun-Young Ahn; Wei-Jong Shia; Nancy A Speck; Dong-Er Zhang
Journal:  Blood       Date:  2013-02-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.